Skip to main content

Vermillion Reports $73K in Q1 Revenues

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Vermillion yesterday filed its form 10-Q with the US Securities and Exchange Commission, in which it reported first-quarter 2010 revenues of $73,000, compared to no revenues for the first quarter of 2009.

For the three months ended March 31, the company's net loss rose to $11.6 million, or $1.14 per diluted share, four times its net loss of $2.8 million, or $0.44 per share, in Q1 2009.

Vermillion reported the figures as part of a bolus of documents filed with the US Securities and Exchange Commission during the past week, as the company caught up on required filings. It had been delinquent on the filings as a result of its Chapter 11 bankruptcy protection, which tied up its resources, the company said.

Vermillion emerged from Chapter 11 in January following clearance from the US Food and Drug Administration for its OVA1 triage ovarian cancer test last fall.

During the first quarter, Vermillion and its partner Quest Diagnostics began marketing the test.

In the first quarter, the company spent $748,000 on R&D, a 39 percent increase from $538,000 in Q1 2009. Expenses for sales, marketing, general and administration purposes increased 46 percent to $2.3 million from $1.6 million.

As of March 31, the company had $37.7 million in cash and cash equivalents.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.